Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Two potential breast cancer susceptibility genes, encoding the BRCA1-interacting proteins ZNF350 (or ZBRK1) and BRIP1 (or BACH1), have been identified in yeast two-hybrid screens. We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer, all of which were negative for BRCA1/BRCA2 mutations. Families had at least one case of male breast cancer, two cases of ovarian cancer, or three or more cases of breast and ovarian cancer. In addition, 58 early-onset (before age 35) breast cancer cases and 30 reference individuals were analyzed. Of 17 variants detected in ZBRK1, a missense mutation Val524Ile was identified in the proband of one high-risk family, but no other family members were available for testing. Of 25 variants identified in BRIP1, in addition to four common silent or missense mutations, we identified Gln540Leu, a non-conservative amino acid change, in a single familial proband with inflammatory breast cancer, but this mutation was not present in her three relatives with breast cancer. Haplotype analysis suggests that all ZBRK1 SNPs fall within a single block with two SNPs capturing 92% of the haplotype diversity, while the BRIP1 SNPs fall in two blocks, with five SNPs capturing 89% of the haplotype diversity. Based on sequencing of ZBRK1 and BRIP1 in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families, it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer. Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to breast cancer in the general population. Hum Mutat 22:121-128, 2003. Published 2003 Wiley-Liss, Inc.
Rutter
Joni L
JL
Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Smith
Amelia M
AM
Dávila
Michael R
MR
Sigurdson
Alice J
AJ
Giusti
Ruthann M
RM
Pineda
Marbin A
MA
Doody
Michele M
MM
Tucker
Margaret A
MA
Greene
Mark H
MH
Zhang
Jinghui
J
Struewing
Jeffery P
JP
D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D050976:Basic-Leucine Zipper Transcription Factors; D001943:Breast Neoplasms / Q000235:genetics*; D018567:Breast Neoplasms, Male / Q000235:genetics*; D004252:DNA Mutational Analysis / Q000379:methods*; D004273:DNA, Neoplasm / Q000235:genetics; D004268:DNA-Binding Proteins; D005190:Family; D051856:Fanconi Anemia Complementation Group Proteins; D005260:Female; D005786:Gene Expression Regulation / Q000235:genetics / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D016350:Leucine Zippers / Q000235:genetics; D015810:Linkage Disequilibrium / Q000235:genetics; D008297:Male; D020125:Mutation, Missense / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics*; D010375:Pedigree; D012097:Repressor Proteins / Q000235:genetics* / Q000502:physiology; D014157:Transcription Factors / Q000235:genetics* / Q000502:physiology; D016335:Zinc Fingers / Q000235:genetics
C102108:BACH1 protein, human; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D050976:Basic-Leucine Zipper Transcription Factors; D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; D051856:Fanconi Anemia Complementation Group Proteins; D012097:Repressor Proteins; D014157:Transcription Factors; C422407:ZNF350 protein, human